T1	intervention 68 77	tamoxifen
T2	control 81 91	raloxifene
T3	eligibility 681 711	high-risk postmenopausal women
T4	duration 713 755	Between July 1, 1999, and November 4, 2004
T5	No-of-participants 757 763	19,747
T6	location 813 826	North America
T7	outcome-Measure 1002 1017	Quality of life
T8	outcome-Measure 904 929	Patient-reported symptoms
T9	outcome-Measure 1442 1499	SF-36 physical (PCS) and mental (MCS) component summaries
T10	outcome 1534 1574	mean PCS, MCS, and CES-D scores worsened
T11	intervention-participants 1670 1673	973
T12	control-participants 1695 1699	1010
T13	No-of-participants 1232 1236	1983
T14	outcome 1716 1731	Sexual function
T15	control-participants 1914 1918	9769
T17	intervention-participants 2021 2025	9743
T18	outcome 2053 2077	musculoskeletal problems
T19	outcome 2104 2115	dyspareunia
T20	outcome 2144 2155	weight gain
T21	intervention-value 2079 2083	1.15
T22	control-value 2087 2091	1.10
T23	intervention-value 2117 2121	0.78
T24	control-value 2125 2129	0.68
T25	intervention-value 2157 2161	0.82
T26	control-value 2165 2169	0.76
T27	outcome 2239 2274	severity for gynecological problems
T28	outcome 2299 2317	vasomotor symptoms
T29	outcome 2342 2352	leg cramps
T30	outcome 2381 2405	bladder control symptoms
T31	intervention-value 2276 2280	0.29
T32	control-value 2284 2288	0.19
T33	intervention-value 2319 2323	0.96
T34	control-value 2327 2331	0.85
T35	intervention-value 2354 2358	1.10
T36	control-value 2362 2366	0.91
T37	intervention-value 2407 2411	0.88
T38	control-value 2415 2419	0.73
T39	outcome 2512 2588	patient-reported outcomes for physical health, mental health, and depression
